Clazakizumab

Clazakizumab (CSL300) is a humanized monoclonal antibody that binds and neutralizes interleukin-6 (IL-6), the main inflammatory cytokine that drives chronic low-grade inflammation in dialysis patients and pushes them toward heart attacks, strokes, and cardiovascular death. CSL Behring is running POSIBIL6ESKD (NCT05485961) [2], a Phase 2b/3 trial in roughly 3,100 adults with end-stage kidney disease on maintenance hemodialysis, testing whether lowering IL-6 translates into fewer major adverse cardiovascular events (MACE). The scientific case was unusually strong on paper: Phase 2b data published in Nature Medicine in May 2024 showed reductions of 86 to 93% in high-sensitivity C-reactive protein (hs-CRP, a blood marker that rises when the body is chronically inflamed) at the top doses, sustained through 24 weeks [1], and human genetics via IL-6 receptor variants independently links lower IL-6 signaling to lower cardiovascular event rates [7]. That case took a serious hit on 2026-07-31 when Novo Nordisk's Phase 3 ZEUS trial of ziltivekimab (NCT05021835), the parallel IL-6 bet in chronic kidney disease, missed its MACE endpoint with a hazard ratio of roughly 0.99 despite on-target engagement [5]. Clazakizumab also failed its own Phase 3 outcomes trial IMAGINE in chronic active antibody-mediated kidney transplant rejection, with early termination for futility [10]. The commercial case in dialysis remains unusually clean because of 20 to 50% annual mortality and almost no new tools since statins underperformed in 4D [8] and AURORA [9], but the probability curve has shifted materially downward since mid-2026.

Clazakizumab originated at Alder Biopharmaceuticals, moved through Vitaeris, and landed at CSL Behring after CSL acquired Vitaeris in 2019. No FDA approval exists for any indication. POSIBIL6ESKD is a two-part adaptive design: Phase 2b is dose-finding with hs-CRP change from baseline as the primary endpoint, and Phase 3 extends into MACE outcomes [2]. Phase 2b results published in Nature Medicine (May 2024) reported dose-dependent, sustained hs-CRP reductions of 86 to 93% at the two highest doses with safety broadly comparable to placebo across 148 randomized patients [1]. Phase 3 is currently enrolling and is event-driven; CSL has publicly guided to a 2029 conclusion window, meaning the realistic MACE readout is a 2028-2029 range absent an early interim [11]. On 2026-02-18, CSL and Eli Lilly signed an exclusive licensing agreement in which Lilly paid $100M upfront plus milestones and royalties for rights to develop clazakizumab in indications outside the ESKD cardiovascular program CSL retains [11]. Lilly initiated a Phase 2 trial under the designation LY5724886 (NCT07783802) in October 2026 in patients with elevated hs-CRP and increased cardiovascular risk outside the dialysis setting [4], extending the asset's addressable population if the ESKD program succeeds. Earlier in clazakizumab's development, Vitaeris and later CSL ran a Phase 3 trial, IMAGINE, in chronic active antibody-mediated kidney transplant rejection (caAMR). That trial was terminated early for futility, and the final analysis showed a least-squares mean eGFR change of -8.0 mL/min/1.73 m² for clazakizumab versus -5.2 for placebo at week 52, with allograft loss or irreversible loss in 28.3% of clazakizumab-treated patients versus 22.2% on placebo [10]. IMAGINE established the drug's safety and PK in renal patients but is a cautionary data point that IL-6 blockade in a different renal context did not translate biomarker modulation into clinical benefit. The compound carries no publicly disclosed breakthrough therapy or fast-track designation for the CV indication.

IL-6 is a cytokine, a signaling protein that immune and other cells release when there is inflammation. In dialysis patients, IL-6 sits chronically elevated because of the dialysis membrane itself, bacterial exposure from vascular access, uremic toxins, and residual uremia, and that chronic signal drives endothelial dysfunction, accelerated atherosclerosis, and muscle wasting. The causal link to cardiovascular disease is unusually well-established for an inflammation target. Mendelian randomization studies using naturally occurring IL-6 receptor variants show that lifelong lower IL-6 signaling tracks with meaningfully lower rates of heart attack, mirroring the effect direction and part of the magnitude seen with LDL lowering [7]. That is a direct human genetic argument, not a mouse model. On the pharmacology side, the CANTOS trial with canakinumab (anti-IL-1 beta, one step upstream of IL-6 in the same pathway) proved in 2017 that cooling inflammation reduces cardiovascular events in people with elevated hs-CRP, independent of lipids [6]. CANTOS failed commercially because of a serious infection signal and modest absolute benefit, but it demonstrated the biology works pharmacologically. Clazakizumab binds free IL-6 directly, blocking it from engaging IL-6R on cells and shutting off downstream JAK-STAT signaling. JAK-STAT is the intracellular relay that translates the IL-6 signal into gene expression; blocking it quiets the inflammatory output inside the cell. Hs-CRP, fibrinogen, and serum amyloid A all drop. The remaining open question, which took on new weight after ZEUS failed, is whether that pharmacological effect translates into hard cardiovascular outcomes in dialysis patients specifically, which is the ESKD-tailored question POSIBIL6ESKD is set up to answer.

POSIBIL6ESKD (NCT05485961) is a two-part Phase 2b/3 study in adults with end-stage kidney disease on maintenance hemodialysis [2]. Phase 2b was dose-finding with hs-CRP change from baseline as the primary endpoint. Phase 3 extends to a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke (MACE). Total planned enrollment is roughly 3,110 patients across both parts, with the trial currently in recruiting status. Phase 2b data published in Nature Medicine (May 2024) covered 148 patients randomized across placebo, 2.5 mg, 5 mg, and 10 mg subcutaneous dosing every four weeks and showed hs-CRP reductions of 86 to 93% at the top two doses sustained through 24 weeks, with no new safety signals of concern [1]. Population PK/PD modeling published in Clinical and Translational Science in 2025 supports flat dosing in Phase 3 [3]. CSL has not publicly disclosed the specific Phase 3 dose selected; the PK/PD paper and the Phase 2b dose-response together imply a dose at or near the 10 mg Q4W level, but the exact Phase 3 regimen is a disclosure gap worth monitoring. The design matches the mechanism well: dialysis patients have the highest baseline inflammation of any studied group, which maximizes effect size and compresses the event rate needed for statistical power. Readout timing is event-driven, not calendar-driven. The main structural question is whether hs-CRP, which Phase 2b hit cleanly, is a reliable surrogate for hard CV outcomes in this specific population. That translation worked for canakinumab in CANTOS [6] and is supported by IL-6R Mendelian randomization [7], but it failed for ziltivekimab in ZEUS in a parallel CKD population, which is the single most important external data point for interpreting this trial [5].

Our model estimates a 12% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 27%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by larger-than-typical enrollment for this phase and more secondary endpoints than usual; it is held back by heavier-than-usual blinding and the sponsor's thin or weak approval record. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Mechanism risk now dominates. ZEUS tested ziltivekimab in roughly 6,300 patients with established atherosclerotic CVD, chronic kidney disease, and elevated hs-CRP and missed the MACE primary endpoint at a hazard ratio near 0.99 despite confirmed target engagement [5]. That is a direct test of the same mechanistic hypothesis clazakizumab is pursuing, in a less inflamed but overlapping population. Clazakizumab bulls will argue that dialysis patients have higher baseline hs-CRP than the ZEUS cohort and therefore more room for benefit; the bear argument is that ZEUS directly rebuts the IL-6-to-MACE translation in CKD. Clazakizumab's own IMAGINE Phase 3 in caAMR was also terminated early for futility, with eGFR change numerically worse on drug than placebo [10]. Different indication, same molecule, same patient class, failed clinical endpoint. Efficacy risk in POSIBIL6ESKD is therefore real and larger than it looked in early 2026. If MACE in the dialysis population is driven more by arrhythmic sudden death, calcification, or non-inflammatory atherothrombosis than by IL-6-driven inflammation, the mechanism may be mistargeted even if the drug does what it does on paper. Statins failed in 4D [8] and AURORA [9] for exactly this reason: the LDL-driven pathway was not the dominant mode of CV death in dialysis. Safety risk centers on infection. Dialysis patients have vascular access-line bacteremia and compromised innate immunity at baseline, and IL-6 blockade adds a known serious-infection signal familiar from tocilizumab in rheumatoid arthritis and from CANTOS fatal sepsis cases [6]. Execution risk is moderate: 3,100 dialysis patients is a slow enrollment, and attrition from death and transplantation complicates follow-up. Commercial risk is lower than for most pipeline assets if the drug is approved, because dialysis patients are concentrated in large chronic care centers with Medicare bundled payment, but the probability of reaching approval has dropped since ZEUS.

Worth watching, but materially re-rated downward since mid-2026. CSL reported FY2026 revenue of US$15.797 billion for the year ended 30 June 2026 [12], so a successful ESKD cardiovascular approval would open a new franchise outside its historical plasma-derived therapy and immunoglobulin business but would not transform the top line. The signal catalyst that was supposed to validate this program was ZEUS, which failed on 2026-07-31 [5]. That failure is the single most important event in this story and the writeup framing has to acknowledge it as a done event, not a future catalyst. CSL de-risked optionality on the asset earlier in 2026 by licensing non-ESKD indications to Eli Lilly for $100M upfront plus milestones and royalties [11], retaining the ESKD CV indication for itself. The Lilly Phase 2 (NCT07783802) in non-dialysis elevated-hs-CRP patients [4] is the parallel bet to watch for mechanism revival outside dialysis. Investors tracking CSL should watch (1) any CSL R&D disclosure on whether POSIBIL6ESKD will be adjusted or continued following ZEUS, including interim analyses or futility stopping rules, (2) the Lilly program readout timeline, which will test whether a different patient population can revive the IL-6-CV thesis post-ZEUS, (3) the specific Phase 3 dose and whether CSL has elected a higher-exposure regimen than ZEUS used, and (4) composition-of-matter patent timing (clazakizumab's core patent family dates to the mid-2000s Alder era, so composition protection is near-term expiring and franchise economics will likely depend on formulation or method-of-use coverage; this should be verified against current CSL patent disclosures before any investment decision). The realistic MACE readout window remains 2028-2029 and is event-driven. This is not investment advice.